In situ quasi-static and dynamic nanoindentation tests on calcified nodules formed by osteoblasts: Implication of glucocorticoids responsible for osteoblast calcification
Source abstract
Abstract
The functional requirements of regenerated calcified tissues are that they enable the tissues to bear a variety of imposed stress and consequent contact-induced strain without substantial fracture. Here we demonstrate the effects of glucocorticoid hormones such as dexamethasone and hydrocortisone on the nanomechanical properties of calcified nodules formed by mouse osteoblastic MC3T3-E1 cells in differentiation-inducing medium containing ascorbic acid and β-glycerophosphate. Neither cell proliferation nor calcium deposition, evaluated using alizarin red and von Kossa staining, was affected by dexamethasone. On the other hand, calcified nodules formed in the presence of dexamethasone were significantly harder and stiffer than those formed in their absence. In particular, a series of nanoindentation tests revealed that the calcified nodules formed in the presence of dexamethasone showed enhanced stiffness against dynamic strain as compared to a quasi-static load. Furthermore, Raman spectroscopy revealed that dexamethasone and hydrocortisone increased the apatite/matrix ratio and lowered that of carbonate in the nodules. Our results suggest that glucocorticoids are required for in vitro formation by osteoblasts of more mature calcified nodules containing apatite/phosphate.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Metal and Thin Film Mechanics · Orthopaedic implants and arthroplasty
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Challenges in tissue engineering10.1098/rsif.2006.0124 ↗
2. The derivation and potential use of human embryonic stem cells10.1071/RD01101 ↗
3. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture10.1016/S8756-3282(97)00276-7 ↗
4. Polyphosphates inhibit extracellular matrix mineralization in MC3T3-E1 osteoblast cultures10.1016/j.bone.2013.01.020 ↗
5. Effect of vitamin C on pre-osteoblast gene expression10.1016/j.archoralbio.2004.11.006 ↗
6. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells10.1002/jbmr.5650070216 ↗
7. Matrix mineralization in MC3T3-E1 cell cultures initiated by β-glycerophosphate pulse10.1016/S8756-3282(98)00139-2 ↗
8. Differential regulation of cadherins by dexamethasone in human osteoblastic cells10.1002/(SICI)1097-4644(20000601)77:3<499::AID-JCB14>3.0.CO;2-0 ↗
9. Determination of the capacity for proliferation and differentiation of osteoprogenitor cells in the presence and absence of dexamethasone10.1016/0012-1606(90)90060-V ↗
10. Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures10.1002/jcp.1041460306 ↗
11. Induction of metallothionein and stimulation of calcification by dexamethasone in cultured clonal osteogenic cells, MC3T3-E110.1016/0378-4274(91)90200-P ↗
12. Human bone cell cultures in biocompatibility testing. Part II: effect of ascorbic acid, β-glycerophosphate and dexamethasone on osteoblastic differentiation10.1016/S0142-9612(99)00192-1 ↗
13. Mechanism of action of β-glycerophosphate on bone cell mineralization10.1007/BF00334492 ↗
14. Secondary osteoporosis: underlying disease and risk for glucocorticoid-induced osteoporosis10.1016/S0149-2918(04)90001-X ↗
15. Dexamethasone suppresses Smad3 pathway in osteoblastic cells10.1677/joe.1.05962 ↗
16. Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3β10.1007/s00774-008-0019-5 ↗
17. Cannabinoid receptor 1 regulates ERK and GSK-3b-dependent glucocorticoid inhibition of osteoblast differentiation in murine MC3T3-E1 cells10.1016/j.bone.2011.08.022 ↗
18. Glucocorticoid receptor and sequential p53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells10.1371/journal.pone.0037030 ↗
19. P53 dependent mitochondrial permeability transition pore opening is required for dexamethasone-induced death of osteoblasts10.1002/jcp.24589 ↗
20. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation10.1359/jbmr.1998.13.12.1822 ↗
21. Osteoblasts isolated from mouse calvaria initiate matrix mineralization in culture10.1083/jcb.96.3.639 ↗
22. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development10.1002/jbmr.5650070613 ↗
23. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential10.1359/jbmr.1999.14.6.893 ↗
24. The von Kossa reaction for calcium deposits: silver lactate staining increases sensitivity and reduces background10.1007/BF00157809 ↗
25. Demonstration of phosphates in calcium deposits: a modification of von Kossa’s reaction10.1007/BF00495978 ↗
26. Measurement of hardness and elastic modulus by instrumented indentation: advances in understanding and refinements to methodology10.1557/jmr.2004.19.1.3 ↗
27. An improved technique for determining hardness and elastic modulus using load and displacement sensing indentation experiments10.1557/JMR.1992.1564 ↗
28. Nanoindentation of biological materials10.1016/S1748-0132(06)70077-9 ↗
29. Lysyl oxidase like-2 reinforces unsatisfactory ossification induced by bone morphogenetic protein-2: relating nanomechanical properties and molecular changes10.1016/j.nano.2013.04.008 ↗
30. In vitro time-dependent response of periodontal ligament to mechanical loading10.1152/japplphysiol.00486.2005 ↗
31. Precision of nanoindentation protocols for measurement of viscoelasticity in cortical and trabecular bone10.1016/j.jbiomech.2010.04.017 ↗
32. Ultrastructural changes accompanying the mechanical deformation of bone tissue: a Raman imaging study10.1007/s00223-002-1039-0 ↗
33. Raman and mechanical properties correlate at whole bone- and tissue-levels in a genetic mouse model10.1016/j.jbiomech.2010.10.009 ↗
34. Mifepristone (RU 486)—a modulator of progestin and glucocorticoid action10.1056/NEJM199308053290607 ↗
35. Microhardness, toughness, and modulus of Mohs scale minerals10.2138/am.2006.1844 ↗
36. Normal bone anatomy and physiology10.2215/CJN.04151206 ↗
37. Induction of carbonic anhydrase in SaOS-2 cells, exposed to bicarbonate and consequences for calcium phosphate crystal formation10.1016/j.biomaterials.2013.07.096 ↗
38. Carbonate-containing apatite (CAP) synthesis under moderate conditions starting from calcium carbonate and orthophosphoric acid10.1016/j.msec.2013.03.023 ↗
39. Preparation and characterisation of monoclinic hydroxyapatite and its precipitated carbonate apatite intermediate10.1016/S0142-9612(99)00225-2 ↗
40. Hardness toughness, and modulus of some common metamorphic minerals10.2138/am.2007.2212 ↗
41. Mohs’s hardness scale—a physical interpretation10.1088/0370-1301/67/3/310 ↗
42. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management10.1016/j.clinthera.2004.12.020 ↗
43. Load-bearing in cortical bone microstructure: selective stiffening and heterogeneous strain distribution at the lamellar level10.1016/j.jmbbm.2012.08.016 ↗
44. A note on unsteady flows of a viscoelastic fluid with the fractional Maxwell model between two parallel plates10.1016/S0020-7462(01)00121-4 ↗
45. Age-related changes in the collagen network and toughness of bone10.1016/S8756-3282(01)00697-4 ↗
46. The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients10.1016/j.bone.2008.05.024 ↗
47. Poroelastic nanoindentation responses of hydrated bone10.1557/JMR.2008.0156 ↗
48. Negative normal stress in semiflexible biopolymer gels10.1038/nmat1810 ↗
49. Glucocorticoid-induced osteoporosis: an update on effects and management10.1016/j.jaci.2013.08.040 ↗
50. Pathogenesis and treatment of steroid osteoporosis10.1111/j.1365-2265.1989.tb03730.x ↗
51. Cushing’s disease10.1186/1750-1172-7-41 ↗
52. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing’s syndrome
53. Metabolic and clinical consequence of hyperthyroidism on bone density10.1155/2013/638727 ↗
54. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength10.1210/en.2003-0990 ↗
55. Glucocorticoids suppress bone formation via the osteoclast10.1172/JCI28084 ↗
56. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids10.1677/joe.0.1590191 ↗
57. Molecular mechanisms of glucocorticoid-induced osteoporosis10.1016/S8756-3282(01)00610-X ↗
58. Sex hormones and glucocorticoids: interactions with the immune system10.1111/j.1749-6632.1999.tb07628.x ↗
59. Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients10.1530/EJE-13-0596 ↗
60. Glucocorticoid receptor signaling in bone cells10.1016/j.molmed.2012.04.005 ↗